Royalty Pharma CFO Terrance P. Coyne Receives Award, Gifts Shares

What Happened

• Terrance P. Coyne, EVP and Chief Financial Officer of Royalty Pharma plc (RPRX), received 11,002 Class A ordinary shares on 2026-08-05 as the settlement of an equity performance award (reported as an exempt acquisition). Two days later (2026-08-07) he disposed of 18,500 shares as a gift. Both transactions were reported on a Form 4 filed 2026-08-07. Each transaction is shown at $0.00 per share because the shares were issued (award) or transferred as a gift, not sold or purchased on the open market.

Key Details

• Transactions and dates:
  • 2026-08-05: Award/settlement — 11,002 Class A shares acquired at $0.00 (exempt acquisition per Rule 16b-3). (Footnote F1)
  • 2026-08-07: Gift — 18,500 shares disposed at $0.00 (reported as a gift/derivative transfer).
• Shares owned after transaction: the filing does not list a simple post-transaction Class A share total, but notes the reporting person and family vehicles hold limited partnership interests exchangeable into 6,448,180 Class A ordinary shares.
• Notable footnotes:
  • F1: Award settlement reported as an exempt acquisition under Rule 16b-3.
  • F2: The filing clarifies that Class E ordinary shares (subject to vesting) can convert one-for-one into Class B shares, which in turn convert one-for-one into Class A shares; conversion rights have no expiration.
• Timeliness: The Form 4 was filed on 2026-08-07 for transactions dated 2026-08-05 and 2026-08-07 — no late filing indication in the report.

Context

• Awards and gifts are not market purchases or sales; grants reflect compensation/vesting events and gifts do not necessarily signal insider sentiment about the stock.
• The $0.00 prices reflect non-market transfers (award issuance or gift). The Rule 16b-3 exemption means the award settlement is treated under the standard insider compensation exemption rather than an open-market purchase.
• The exchangeable limited partnership interests noted in the remarks represent additional potential economic exposure (6,448,180 Class A share equivalent) beyond the specific shares reported in these transactions.